Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GILD Gilead Sciences	$118.73 +0.6%	$112.33	$74.80 ▼ $121.83	$146.39B	0.33	6.66 million shs	5.62 million shs
LLY Eli Lilly and Company	$704.75 +0.2%	$758.91	$623.78 ▼ $972.53	$665.56B	0.44	6.86 million shs	4.13 million shs
MDT Medtronic	$93.13 +3.6%	$89.57	$79.29 ▼ $96.25	$115.23B	0.8	7.34 million shs	13.23 million shs
PFE Pfizer	$25.38 +0.2%	$24.66	$20.92 ▼ $30.43	$143.96B	0.52	44.16 million shs	38.06 million shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GILD Gilead Sciences	-0.01%	-1.70%	+9.02%	+9.52%	+58.47%
LLY Eli Lilly and Company	+0.67%	+10.02%	-8.84%	-2.86%	-23.68%
MDT Medtronic	-3.04%	-2.36%	+0.32%	+6.38%	+6.01%
PFE Pfizer	+0.90%	+2.68%	+3.41%	+9.70%	-12.22%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GILD Gilead Sciences	4.9515 of 5 stars	2.4	5.0	4.2	4.1	3.4	2.5	2.5
LLY Eli Lilly and Company	5 of 5 stars	4.3	5.0	3.3	4.0	3.8	3.3	2.5
MDT Medtronic	4.8149 of 5 stars	2.3	5.0	3.3	4.1	3.9	1.7	1.9
PFE Pfizer	4.8561 of 5 stars	2.2	3.0	4.2	4.5	3.3	1.7	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GILD Gilead Sciences	2.88	Moderate Buy	$115.39	-2.81% Downside
LLY Eli Lilly and Company	2.65	Moderate Buy	$950.17	34.82% Upside
MDT Medtronic	2.59	Moderate Buy	$98.63	5.90% Upside
PFE Pfizer	2.39	Hold	$28.12	10.81% Upside

Current Analyst Ratings Breakdown

Latest GILD, MDT, PFE, and LLY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/20/2025	MDT Medtronic	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$94.00 ➝ $95.00
8/20/2025	MDT Medtronic	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$98.00 ➝ $100.00
8/20/2025	MDT Medtronic	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$97.00 ➝ $98.00
8/20/2025	MDT Medtronic	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$94.00 ➝ $96.00
8/19/2025	GILD Gilead Sciences	Daiwa America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/19/2025	GILD Gilead Sciences	Daiwa Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Outperform	$128.00
8/17/2025	LLY Eli Lilly and Company	Daiwa Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$700.00
8/17/2025	LLY Eli Lilly and Company	Daiwa America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/14/2025	LLY Eli Lilly and Company	DZ Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/14/2025	MDT Medtronic	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
8/13/2025	LLY Eli Lilly and Company	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$975.00 ➝ $825.00

(Data available from 8/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GILD Gilead Sciences	$28.75B	5.12	$6.91 per share	17.17	$15.79 per share	7.52
LLY Eli Lilly and Company	$45.04B	14.81	$14.27 per share	49.40	$19.39 per share	36.35
MDT Medtronic	$33.54B	3.56	$8.03 per share	11.60	$37.62 per share	2.48
PFE Pfizer	$63.63B	2.27	$4.38 per share	5.80	$15.66 per share	1.62

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GILD Gilead Sciences	$480M	$5.02	23.65	14.64	0.72	21.86%	50.99%	17.24%	11/5/2025 (Estimated)
LLY Eli Lilly and Company	$10.59B	$15.30	46.06	22.65	0.98	25.91%	92.72%	16.89%	10/29/2025 (Estimated)
MDT Medtronic	$4.66B	$3.63	25.66	15.97	2.33	13.63%	14.56%	7.85%	N/A
PFE Pfizer	$8.03B	$1.88	13.50	8.37	0.90	16.84%	21.42%	9.12%	11/4/2025 (Estimated)

Latest GILD, MDT, PFE, and LLY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/19/2025	Q1 2026	MDT Medtronic	$1.23	$1.26	+$0.03	$0.81	$8.37 billion	$8.58 billion
8/7/2025	Q2 2025	GILD Gilead Sciences	$1.96	$2.01	+$0.05	$1.55	$6.95 billion	$7.08 billion
8/7/2025	Q2 2025	LLY Eli Lilly and Company	$5.59	$6.31	+$0.72	$6.29	$14.40 billion	$15.56 billion
8/5/2025	Q2 2025	PFE Pfizer	$0.58	$0.78	+$0.20	$0.51	$13.43 billion	$14.65 billion
5/21/2025	Q4 2025	MDT Medtronic	$1.58	$1.62	+$0.04	$0.82	$8.81 billion	$8.93 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GILD Gilead Sciences	$3.16	2.66%	N/A	62.95%	10 Years
LLY Eli Lilly and Company	$6.00	0.85%	N/A	39.22%	11 Years
MDT Medtronic	$2.84	3.05%	N/A	78.24%	49 Years
PFE Pfizer	$1.72	6.78%	N/A	91.49%	16 Years

Latest GILD, MDT, PFE, and LLY Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
8/15/2025	MDT Medtronic	quarterly	$0.71	3.1%	9/26/2025	9/26/2025	10/17/2025
7/29/2025	GILD Gilead Sciences	quarterly	$0.79	2.7%	9/15/2025	9/15/2025	9/29/2025
6/23/2025	LLY Eli Lilly and Company	quarterly	$1.50	0.78%	8/15/2025	8/15/2025	9/10/2025
6/25/2025	PFE Pfizer	quarterly	$0.43	7.08%	7/25/2025	7/25/2025	9/2/2025
5/21/2025	MDT Medtronic	quarterly	$0.71	3.3%	6/27/2025	6/27/2025	7/11/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GILD Gilead Sciences	1.13	1.32	1.15
LLY Eli Lilly and Company	1.86	1.28	1.00
MDT Medtronic	0.53	1.85	1.42
PFE Pfizer	0.65	1.16	0.85

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GILD Gilead Sciences	83.67%
LLY Eli Lilly and Company	82.53%
MDT Medtronic	82.06%
PFE Pfizer	68.36%

Insider Ownership

Company	Insider Ownership
GILD Gilead Sciences	0.27%
LLY Eli Lilly and Company	0.13%
MDT Medtronic	0.20%
PFE Pfizer	0.06%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GILD Gilead Sciences	17,600	1.24 billion	1.24 billion	Optionable
LLY Eli Lilly and Company	47,000	946.46 million	945.23 million	Optionable
MDT Medtronic	95,000	1.28 billion	1.28 billion	Optionable
PFE Pfizer	81,000	5.69 billion	5.68 billion	Optionable

GILD, MDT, PFE, and LLY Headlines

Recent News About These Companies

How Much Would It Take To Earn $100 A Month From Pfizer Stock

2 hours ago | finance.yahoo.com

New Bill: Representative Brian K. Fitzpatrick introduces H.R. 4993: Joe Fiandra Access to Home Infusion Act of 2025

August 20 at 12:11 PM | quiverquant.comQ

Pfizer sued by Enanta in EU over patent infringement related to COVID pill

August 20 at 8:30 AM | seekingalpha.com

Enanta Pharmaceuticals Sues Pfizer Over Patent Infringement

August 20 at 7:50 AM | tipranks.com

Venture Visionary Partners LLC Has $10.06 Million Position in Pfizer Inc. $PFE

August 20 at 7:10 AM | marketbeat.com

Banco Bilbao Vizcaya Argentaria S.A. Buys 456,583 Shares of Pfizer Inc. $PFE

August 20 at 6:38 AM | marketbeat.com

Berkshire Asset Management LLC PA Cuts Stock Position in Pfizer Inc. $PFE

August 20 at 6:28 AM | marketbeat.com

My Top Dividend-Paying, Deep-Value Stock to Buy in August

August 20 at 6:05 AM | fool.com

Paradigm Capital Management LLC NV Trims Holdings in Pfizer Inc. $PFE

August 20 at 5:45 AM | marketbeat.com

Why Pfizer’s (PFE) Oncology Gamble is Finally Paying Off

August 19 at 12:24 AM | msn.com

Pfizer Oncology Drugs Drive Sales in Q2: Will the Trend Continue?

August 19 at 10:10 AM | zacks.com

BNP PARIBAS ASSET MANAGEMENT Holding S.A. Decreases Stock Holdings in Pfizer Inc. $PFE

August 19 at 9:12 AM | marketbeat.com

Wellington Management Group LLP Sells 36,497,190 Shares of Pfizer Inc. $PFE

August 19 at 8:10 AM | marketbeat.com

Edgar Lomax Co. VA Has $20.41 Million Stock Holdings in Pfizer Inc. $PFE

August 19 at 8:08 AM | marketbeat.com

Korea Investment CORP Sells 556,393 Shares of Pfizer Inc. $PFE

August 19 at 7:58 AM | marketbeat.com

Northern Trust Corp Grows Position in Pfizer Inc. $PFE

August 19 at 7:09 AM | marketbeat.com

Is Pfizer's 6.8%-Yielding Dividend Too Good to Be True?

August 19 at 5:50 AM | fool.com

Is Pfizer's 6.8%-Yielding Dividend Too Good to Be True?

August 19 at 4:50 AM | fool.com

American Century Companies Inc. Sells 122,607 Shares of Pfizer Inc. $PFE

August 19 at 4:26 AM | marketbeat.com

Pfizer Inc. (NYSE:PFE) Receives $28.12 Average PT from Brokerages

August 19 at 2:07 AM | americanbankingnews.com

Health Canada Approves Pfizer's (PFE) Updated COVID-19 Vaccine for 2025-26

August 18 at 6:11 PM | gurufocus.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

GILD, MDT, PFE, and LLY Company Descriptions

Gilead Sciences NASDAQ:GILD

$118.73 +0.75 (+0.64%)

Closing price 04:00 PM Eastern

Extended Trading

$117.42 -1.31 (-1.10%)

As of 07:57 PM Eastern

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Eli Lilly and Company NYSE:LLY

$704.75 +1.54 (+0.22%)

Closing price 03:59 PM Eastern

Extended Trading

$703.50 -1.25 (-0.18%)

As of 07:59 PM Eastern

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Medtronic NYSE:MDT

$93.13 +3.23 (+3.60%)

Closing price 03:59 PM Eastern

Extended Trading

$92.90 -0.24 (-0.25%)

As of 07:54 PM Eastern

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Pfizer NYSE:PFE

$25.38 +0.06 (+0.22%)

Closing price 03:59 PM Eastern

Extended Trading

$25.36 -0.02 (-0.08%)

As of 07:59 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time